Certified breast centres are requested to recruit patients in prospective clinical trials.
Currently open and planned studies, coordinated by the following organisations:
- International Breast Cancer Study Group (IBCSG)
- Swiss Group for Clinical Cancer Research (SAKK)
- European Organisation for Research and Treatment of Cancer (EORTC)
Please send information about new studies to: email@example.com
Prospective part: Clinical and biological characterization of Male Breast Cancer: an international EORTC, BIG and NABCG intergroup study.
A phase 3 randomized trial of Niraparib versus Physician's choice in patients with germline BRCA mutation and previously treated breast cancer.
A phase II randomized, Double-blind, parallel cohort study of neoadjuvant letrozole + GDC-0032 vs Letrozole + Placebo on Post Menopausal Women with ER+/HER2- primary breast cancer.
A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy
Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer
EORTC 75111 / 10114
Pertuzumab + trastuzumab (PH) versus PH plus metronomic chemotherapy (PHM) in the elderly HER2+ metastatic breast cancer population who may continue on T-DM1 alone following disease progression while on PH/PHM: an open-label multicentre randomized phase II selection trial of the EORTC Elderly Task Force and Breast Cancer Group
EORTC 90091 / 10093
TRastuzumab in HER2-negative Early breast cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC) ("Treat CTC" trial)
IBCSG 41-13 TREND
A randomized phase II Trial evaluating the endocrine activity and efficacy of neoadjuvant degarelix versus triptorelin in premenopausal patients receiving letrozole for Primary endocrine responsive breast cancer.
IBCSG 45-13 PANACEA
A phase Ib/II trial evaluating the efficacy of MK-3475 and trastuzumab in patients with trastuzumab-resistant, HER2-positive metastatic breast cancers.
IBCSG 46-13 LORELEI
A phase II randomized, double-blind study of neoadjuvant Letrozole Plus GDC-0032 versus Letrozole Plus placebo in postmenopausal women with ER-positive/HER2-negative, early stage breast cancer.
IBCSG 47-14 BRAVO
A phase III, randomized, open label, multicenter, controlled trial of niraparib versus physician’s choice in previously-treated, HER2 negative, germline BRCA mutation-positive breast cancer patients.
IBCSG 48-14 POSITIVE
A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy.
IBCSG 49-14 PENELOPE
Phase III study evaluating palbociclib (PD-0332991), a CyclinDependent Kinase (CDK) 4/6 Inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy.
IBCSG 50-14 OLYMPIA
A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.
IBCSG 51-14 AURORA
Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.
Impact of a Surgical Sealing Patch on Lymphatic Drainage after Axillary Lymph Node Dissection for Breast Cancer.
Eribulin 1st line in elderly (= 70 years) and old patients (> 80 y) with metastatic breast cancer: a phase II trial
Treatment of patients with bone metastases using Xgeva® - Prevention of symptomatic skeletal complications with denosumab administered every 4 weeks versus every 12 weeks.
Management of low risk ductal carcinoma in situ (low-risk DCIS): a randomized, multicentre, non-inferiority trial, between standard therapy approach versus active surveillance.
Geschäftsstelle Q-Label Krebsliga Schweiz
Tel. 031 389 91 60